CTOs on the Move

EUSA Pharma

www.eusapharma.com

 
EUSA Pharma is a specialty pharma company with a strong and growing portfolio of specialty hospital medicines. It has been built through the acquisition of Talisker Pharmaceuticals in July 2006 and OPi in March 2007. Our primary marketed products are
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.eusapharma.com
  • 1717 Langhorne Newtown Rd Ste 201
    Langhorne, PA USA 19047
  • Phone: 215.867.4900

Executives

Name Title Contact Details

Similar Companies

CardioRisk

CardioRisk is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LandsteinerScientific

LandsteinerScientific is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Carrollwood Pharmacy

Carrollwood Pharmacy is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioBlast Pharma

BioBlast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The Company is building a diverse portfolio of product candidates with the potential to address unmet medical needs for incurable diseases. The BioBlast platforms are based on deep understandings of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology.

Vernalis

Vernalis plc is a revenue generating development stage pharmaceutical company with one marketed product, frovatriptan, and a broad pipeline of research and development programmes. The business model is a balance between risk and innovation with the aim of creating value through a focused and disciplined strategy. An exclusive development and licensing agreement with Tris Pharma to develop multiple novel products focussed on the US prescription cough cold market is the platform for Vernalis to build a profitable and cash generative commercial business in the US. These novel products are low risk, late stage and differentiated for an unmet need. Value is also being extracted from the legacy NCE pipeline where the model is to selectively invest and then partner these programmes, earning milestones and royalties as partners progress them at their expense. Vernalis also exploits its significant expertise in fragment and structure based drug discovery by entering into collaborations with larger pharmaceutical companies. Its technologies and capabilities have been endorsed, over the last five years, through collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris Pharma.